Gelesis Holdings, Inc. (GLSHQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jun 13, 2025
0.00%
Market Cap73.00
Revenue (ttm)12.14M
Net Income (ttm)-51.67M
Shares Out73.34M
EPS (ttm)-0.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume999
Average Volume19,246
Open0.0000
Previous Close0.0000
Day's Range0.0000 - 0.0000
52-Week Rangen/a
Beta3,078.68
RSI45.97
Earnings Daten/a

About Gelesis Holdings

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 93
Stock Exchange OTCMKTS
Ticker Symbol GLSHQ
Full Company Profile

Financial Performance

In 2022, Gelesis Holdings's revenue was $25.77 million, an increase of 130.37% compared to the previous year's $11.19 million. Losses were -$95.06 million, -49.40% less than in 2021.

Financial Statements

News

There is no news available yet.